Presentation is loading. Please wait.

Presentation is loading. Please wait.

Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black.

Published byIvan Darmali Modified over 5 years ago

Similar presentations

Presentation on theme: "Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black."— Presentation transcript:

1 Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black line for conventional) (B), and DCCT primary prevention vs. secondary intervention cohort (black line for primary prevention) (C). Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black line for conventional) (B), and DCCT primary prevention vs. secondary intervention cohort (black line for primary prevention) (C). Data are means ± SE at each DCCT/EDIC follow-up year. Barbara H. Braffett et al. Dia Care 2019;42: ©2019 by American Diabetes Association

Download ppt "Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black."

Similar presentations

The Relationship of Urologic Complications With Health- Related Quality of Life and Perceived Value of Health in Men and Women with Type 1 Diabetes: The.

The Relationship of Urologic Complications With Health- Related Quality of Life and Perceived Value of Health in Men and Women with Type 1 Diabetes: The.
Copyright © 2008 American Medical Association. All rights reserved.

Copyright © 2008 American Medical Association. All rights reserved.
New Patient-Friendly Options for Managing Insulin Dosing

New Patient-Friendly Options for Managing Insulin Dosing
The cumulative incidence of any major eye disease end point (PDR, CSME, application of laser, or development of blindness) is shown in relation to diabetes.

The cumulative incidence of any major eye disease end point (PDR, CSME, application of laser, or development of blindness) is shown in relation to diabetes.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
The risk of DR progression as related to mean HbA1c during DCCT

The risk of DR progression as related to mean HbA1c during DCCT
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.
Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.
Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.
Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.
Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs7903146 polymorphism and the dietary intervention group after.

Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs polymorphism and the dietary intervention group after.
Group differences (DKA vs

Group differences (DKA vs
Temporal patterns of insulin sensitivity (A), C-peptide index (B), C-peptide oDI (C), and HMWA (D) in the three racial/ethnic groups with the three treatments.

Temporal patterns of insulin sensitivity (A), C-peptide index (B), C-peptide oDI (C), and HMWA (D) in the three racial/ethnic groups with the three treatments.
A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.
Glucose, insulin, and AGE levels during an OGC before and after RT

Glucose, insulin, and AGE levels during an OGC before and after RT
Incidences (%) for the development (for individuals without MetS at baseline, n = 125) (□) and the resolution (for individuals with MetS at baseline, n.

Incidences (%) for the development (for individuals without MetS at baseline, n = 125) (□) and the resolution (for individuals with MetS at baseline, n.
Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.
The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

Similar presentations

Ads by Google